217 related articles for article (PubMed ID: 19811811)
41. A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies.
Wuthrick EJ; Kamrava M; Curran WJ; Werner-Wasik M; Camphausen KA; Hyslop T; Axelrod R; Andrews DW; Glass J; Machtay M; Dicker AP
Cancer; 2011 Dec; 117(24):5548-59. PubMed ID: 21647871
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.
Josephs D; Hutson TE; Cowey CL; Pickering LM; Larkin JM; Gore ME; Van Hemelrijck M; McDermott DF; Powles T; Chowdhury P; Karapetis C; Harper PG; Choueiri TK; Chowdhury S
BJU Int; 2011 Oct; 108(8):1279-83. PubMed ID: 21244613
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and toxicity of sunitinib in metastatic renal cell carcinoma patients in Egypt.
Edesa WA; Abdelmalek RR
Asian Pac J Cancer Prev; 2015; 16(5):1971-6. PubMed ID: 25773796
[TBL] [Abstract][Full Text] [Related]
44. Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study.
Robert F; Sandler A; Schiller JH; Liu G; Harper K; Verkh L; Huang X; Ilagan J; Tye L; Chao R; Traynor AM
Cancer Chemother Pharmacol; 2010 Sep; 66(4):669-80. PubMed ID: 20043166
[TBL] [Abstract][Full Text] [Related]
45. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
46. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.
Thomas A; Rajan A; Berman A; Tomita Y; Brzezniak C; Lee MJ; Lee S; Ling A; Spittler AJ; Carter CA; Guha U; Wang Y; Szabo E; Meltzer P; Steinberg SM; Trepel JB; Loehrer PJ; Giaccone G
Lancet Oncol; 2015 Feb; 16(2):177-86. PubMed ID: 25592632
[TBL] [Abstract][Full Text] [Related]
47. Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience.
Coelho RC; Reinert T; Campos F; Peixoto FA; de Andrade CA; Castro T; Herchenhorn D
Int Braz J Urol; 2016; 42(4):694-703. PubMed ID: 27564279
[TBL] [Abstract][Full Text] [Related]
48. Phase II open-label study of sunitinib in patients with advanced breast cancer.
Yardley DA; Dees EC; Myers SD; Li S; Healey P; Wang Z; Brickman MJ; Paolini J; Kern KA; Citrin DL
Breast Cancer Res Treat; 2012 Dec; 136(3):759-67. PubMed ID: 23073758
[TBL] [Abstract][Full Text] [Related]
49. A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis.
Jo JC; Hong YS; Kim KP; Lee JL; Lee J; Park YS; Kim SY; Ryu JS; Lee JS; Kim TW
Invest New Drugs; 2014 Apr; 32(2):369-76. PubMed ID: 24425345
[TBL] [Abstract][Full Text] [Related]
50. Mitoxantrone in the treatment of advanced uterine sarcoma. A phase II trial of the Gynecologic Oncology Group.
Muss HB; Bundy BN; Adcock L; Beecham J
Am J Clin Oncol; 1990 Feb; 13(1):32-4. PubMed ID: 2154921
[TBL] [Abstract][Full Text] [Related]
51. A phase II and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers.
Wu C; Mikhail S; Wei L; Timmers C; Tahiri S; Neal A; Walker J; El-Dika S; Blazer M; Rock J; Clark DJ; Yang X; Chen JL; Liu J; Knopp MV; Bekaii-Saab T
Br J Cancer; 2015 Jul; 113(2):220-5. PubMed ID: 26151457
[TBL] [Abstract][Full Text] [Related]
52. Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer.
De Giorgi U; Rihawi K; Aieta M; Lo Re G; Sava T; Masini C; Baldazzi V; De Vincenzo F; Camerini A; Fornarini G; Burattini L; Rosti G; Moscetti L; Chiuri VE; Luzi Fedeli S; Ferrari V; Scarpi E; Amadori D; Basso U
J Geriatr Oncol; 2014 Apr; 5(2):156-63. PubMed ID: 24495699
[TBL] [Abstract][Full Text] [Related]
53. Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study.
Miller DS; Blessing JA; Kilgore LC; Mannel R; Van Le L
Am J Clin Oncol; 2000 Aug; 23(4):355-7. PubMed ID: 10955863
[TBL] [Abstract][Full Text] [Related]
54. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
55. Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
Motzer RJ; Hutson TE; Cella D; Reeves J; Hawkins R; Guo J; Nathan P; Staehler M; de Souza P; Merchan JR; Boleti E; Fife K; Jin J; Jones R; Uemura H; De Giorgi U; Harmenberg U; Wang J; Sternberg CN; Deen K; McCann L; Hackshaw MD; Crescenzo R; Pandite LN; Choueiri TK
N Engl J Med; 2013 Aug; 369(8):722-31. PubMed ID: 23964934
[TBL] [Abstract][Full Text] [Related]
56. A pilot study of hypofractionated stereotactic radiation therapy and sunitinib in previously irradiated patients with recurrent high-grade glioma.
Wuthrick EJ; Curran WJ; Camphausen K; Lin A; Glass J; Evans J; Andrews DW; Axelrod R; Shi W; Werner-Wasik M; Haacke EM; Hillman GG; Dicker AP
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):369-75. PubMed ID: 25104067
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study.
Gallup DG; Blessing JA; Andersen W; Morgan MA;
Gynecol Oncol; 2003 Apr; 89(1):48-51. PubMed ID: 12694653
[TBL] [Abstract][Full Text] [Related]
58. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184.
Mackay HJ; Tinker A; Winquist E; Thomas G; Swenerton K; Oza A; Sederias J; Ivy P; Eisenhauer EA
Gynecol Oncol; 2010 Feb; 116(2):163-7. PubMed ID: 19740535
[TBL] [Abstract][Full Text] [Related]
59. Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: A single-arm phase II study (EORTC-08061).
Abdelraouf F; Smit E; Hasan B; Menis J; Popat S; van Meerbeeck JP; Surmont VF; Baas P; O'Brien M
Eur J Cancer; 2016 Feb; 54():35-39. PubMed ID: 26716400
[TBL] [Abstract][Full Text] [Related]
60. A pilot study of sunitinib malate in patients with metastatic uveal melanoma.
Mahipal A; Tijani L; Chan K; Laudadio M; Mastrangelo MJ; Sato T
Melanoma Res; 2012 Dec; 22(6):440-6. PubMed ID: 23114504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]